Results 231 to 240 of about 123,362 (289)

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Comparison of N-Terminal Pro-B-Type Natriuretic Peptide Between Cats with Cardiogenic Arterial Thromboembolism and Cats with Occult Cardiomyopathy Without Arterial Thromboembolism. [PDF]

Animals (Basel)
Oranges MA, Freeman LM, Rozanski EA, Karlin ET, Rush JE.   +4 more
europepmc   +1 more source

Correction to ‘Natriuretic peptides and C‐reactive protein in in heart failure and malnutrition: A systematic review and meta‐analysis’

ESC Heart Failure, Volume 12, Issue 2, Page 1524-1524, April 2025.
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

The Role of Epicardial Fat Thickness and B-type Natriuretic Peptide (BNP)/N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) in Heart Failure Risk Stratification: A Systematic Review. [PDF]

Cureus
Osman Mohamed AA, Bashir Omer SS, Mukhtar M, Mohmmed T, Hussein Mohamed WM, Mohamed Hassan MH, Mohammed Hassan I.   +6 more
europepmc   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone, Erik Moedt, Hiddo J. L. Heerspink, Michael J. Davies, Manon Girard, David Z. I. Cherney, Marcel H. A. Muskiet   +6 more
wiley   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Proteome-Wide Mendelian Randomization Identifies Natriuretic Peptide-B and Novel Proteins as Potential Regulators of Pulse Pressure in Humans. [PDF]

J Am Heart Assoc
Dib MJ, Meena D, Yarmolinsky J, Azzo JD, Salman O, Tavolinejad H, Gan S, Beeche C, Pourmussa B, Gill D, Burgess S, Chirinos JA.   +11 more
europepmc   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Beyond Traditional Risk Factors: Inflammation, Asymmetric Dimethylarginine, and N-Terminal pro-B-Type Natriuretic Peptide Predict Cardiovascular Risk in Chronic Kidney Disease. [PDF]

Cureus
Hoxha E, Collaku L, Kuka S, Seferi S, Pojani P, Habilaj X, Kambo M, Zaimi Petrela E, Bulo A, Resuli M.   +9 more
europepmc   +1 more source